Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3B, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Double-Dummy, Study Of The Efficacy And Safety Of Apremilast (CC-10004), Etanercept, And Placebo, In Subjects With Moderate To Severe Plaque Psoriasis
Brief Summary: This study will test the clinical effectiveness and safety of apremilast compared with placebo as well as etanercept compared with placebo in the same group of patients with moderate to severe plaque psoriasis.


Options:
A: Arm Label: Apremilast 30 mg plus placebo injection; Type: EXPERIMENTAL; Interventions: Drug: Apremilast, Drug: Placebo injection | Arm Label: Etanercept 50 mg plus placebo tablet; Type: EXPERIMENTAL; Interventions: Drug: Etanercept, Drug: Placebo tablet | Arm Label: Oral placebo tablets plus SC placebo injections; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo tablet, Drug: Placebo injection | Intervention Type: DRUG; Name: Apremilast; Assigned to Arm(s): Apremilast 30 mg plus placebo injection | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): Etanercept 50 mg plus placebo tablet | Intervention Type: DRUG; Name: Placebo tablet; Assigned to Arm(s): Etanercept 50 mg plus placebo tablet, Oral placebo tablets plus SC placebo injections | Intervention Type: DRUG; Name: Placebo injection; Assigned to Arm(s): Apremilast 30 mg plus placebo injection, Oral placebo tablets plus SC placebo injections
B: Arm Label: Group I; Type: EXPERIMENTAL; Interventions: Drug: Guselkumab 100 mg, Drug: Placebo for guselkumab, Drug: Placebo for adalimumab | Arm Label: Group II; Type: PLACEBO_COMPARATOR; Interventions: Drug: Guselkumab 100 mg, Drug: Placebo for guselkumab, Drug: Placebo for adalimumab | Arm Label: Group III; Type: ACTIVE_COMPARATOR; Interventions: Drug: Guselkumab 100 mg, Drug: Placebo for guselkumab, Drug: Adalimumab | Intervention Type: DRUG; Name: Guselkumab 100 mg; Assigned to Arm(s): Group I, Group II, Group III | Intervention Type: DRUG; Name: Placebo for guselkumab; Assigned to Arm(s): Group I, Group II, Group III | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): Group III | Intervention Type: DRUG; Name: Placebo for adalimumab; Assigned to Arm(s): Group I, Group II
C: Arm Label: AIN457 150mg; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: secukinumab (AIN457) | Arm Label: AIN457 300mg; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: secukinumab (AIN457) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Etanercept; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo, Drug: etanercept | Arm Label: AIN457 150mg from Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: secukinumab (AIN457) | Arm Label: AIN457 300mg from Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: secukinumab (AIN457) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): AIN457 150mg, AIN457 150mg from Placebo, AIN457 300mg, AIN457 300mg from Placebo, Etanercept, Placebo | Intervention Type: DRUG; Name: secukinumab (AIN457); Assigned to Arm(s): AIN457 150mg, AIN457 150mg from Placebo, AIN457 300mg, AIN457 300mg from Placebo | Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): Etanercept
D: Arm Label: Anti-TNFa regimen; Type: ACTIVE_COMPARATOR; Interventions: Drug: etanercept | Arm Label: Anti IL12/23 regimen; Type: ACTIVE_COMPARATOR; Interventions: Drug: ustekinumab | Arm Label: Cyclosporine regimen; Type: ACTIVE_COMPARATOR; Interventions: Drug: cyclosporine | Arm Label: anti-interleukin 17 A regimen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Secukinumab | Arm Label: inhibitor of phosphodiesterase-4; Type: ACTIVE_COMPARATOR; Interventions: Drug: Apremilast | Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): Anti-TNFa regimen | Intervention Type: DRUG; Name: ustekinumab; Assigned to Arm(s): Anti IL12/23 regimen | Intervention Type: DRUG; Name: cyclosporine; Assigned to Arm(s): Cyclosporine regimen | Intervention Type: DRUG; Name: Secukinumab; Assigned to Arm(s): anti-interleukin 17 A regimen | Intervention Type: DRUG; Name: Apremilast; Assigned to Arm(s): inhibitor of phosphodiesterase-4

Answer: A